Intellia Therapeutics (NTLA) Profit After Tax (2016 - 2025)
Historic Profit After Tax for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$101.3 million.
- Intellia Therapeutics' Profit After Tax rose 2533.9% to -$101.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.8 million, marking a year-over-year increase of 1464.3%. This contributed to the annual value of -$519.0 million for FY2024, which is 786.15% down from last year.
- Intellia Therapeutics' Profit After Tax amounted to -$101.3 million in Q3 2025, which was up 2533.9% from -$101.3 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Profit After Tax registered a high of -$46.2 million during Q1 2021, and its lowest value of -$147.0 million during Q2 2024.
- Its 5-year average for Profit After Tax is -$108.4 million, with a median of -$113.2 million in 2022.
- Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 21787.04% in 2022, then soared by 3110.73% in 2025.
- Intellia Therapeutics' Profit After Tax (Quarter) stood at -$81.2 million in 2021, then crashed by 39.6% to -$113.4 million in 2022, then dropped by 16.54% to -$132.2 million in 2023, then increased by 2.47% to -$128.9 million in 2024, then increased by 21.39% to -$101.3 million in 2025.
- Its last three reported values are -$101.3 million in Q3 2025, -$101.3 million for Q2 2025, and -$114.3 million during Q1 2025.